Results 21 to 30 of about 39,213 (240)

Research Models for Studying Vascular Calcification [PDF]

, 2020
Calcification of the vessel wall contributes to high cardiovascular morbidity and mortality. Vascular calcification (VC) is a systemic disease with multifaceted contributing and inhibiting factors in an actively regulated process.
Babic, Milen, Giet, Markus van der, Herrmann, Jaqueline, Schuchardt, Mirjam, Tölle, Markus   +4 more
core   +1 more source

Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes

Cardiovascular Diabetology, 2013
Background Osteoprotegerin is a member of the tumor necrosis factor-related family and inhibits RANK stimulation of osteoclast formation as a soluble decoy receptor.
Aoki Atsushi, Murata Miho, Asano Tomoko, Ikoma Aki, Sasaki Masami, Saito Tomoyuki, Otani Taeko, Jinbo Sachimi, Ikeda Nahoko, Kawakami Masanobu, Ishikawa San-e   +10 more
doaj   +1 more source

Interleukin-19 promotes bone resorption by suppressing osteoprotegerin expression in BMSCs in a lipopolysaccharide-induced bone loss mouse model

Bone & Joint Research, 2023
Aims: Osteoporosis is characterized by decreased trabecular bone volume, and microarchitectural deterioration in the medullary cavity. Interleukin-19 (IL-19), a member of the IL-10 family, is an anti-inflammatory cytokine produced primarily by ...
Zhicheng Dai, Yanan Chen, Enjun He, Hongjie Wang, Weihong Guo, Zhenkai Wu, Kai Huang, Qinghua Zhao   +7 more
doaj   +1 more source

Serum OPG and RANKL Levels as Risk Factors for the Development of Cardiovascular Calcifications in End-Stage Renal Disease Patients in Hemodialysis

Life, 2023
Cardiovascular calcifications (CVC) are frequently observed in chronic kidney disease (CKD) patients and contribute to their cardiovascular mortality. The aim of the present study was to investigate the impact of osteoprotegerin (OPG)/Receptor Activator ...
Michalis Spartalis, Efstratios Kasimatis, Eleni Liakou, Erasmia Sampani, Georgios Lioulios, Michalis Christodoulou, Stamatia Stai, Eleni Moysidou, George Efstratiadis, Aikaterini Papagianni   +9 more
doaj   +1 more source

Serum Osteoprotegerin Level Is Negatively Associated with Bone Mineral Density in Patients Undergoing Maintenance Hemodialysis

Medicina, 2021
Background and Objectives: Osteoprotegerin (OPG), a potent osteoclast activation inhibitor, decreases bone resorption and plays a role in mediating bone mineral density (BMD).
Chia-Wen Lu, Chih-Hsien Wang, Bang-Gee Hsu, Jen-Pi Tsai   +3 more
doaj   +1 more source

Positioning novel biologicals in CKD-mineral and bone disorders [PDF]

, 2017
Renal osteodystrophy (ROD), the histologic bone lesions of chronic kidney disease (CKD), is now included in a wider syndrome with laboratory abnormalities of mineral metabolism and extra-skeletal calcifications or CKD-mineral and bone disorders (CKD-MBD),
Covic, Adrian, Mazzaferro, Sandro, Muci, MARIA LUISA, Pasquali, Marzia, Rotondi, Silverio, Tartaglione, Lida   +5 more
core   +1 more source

Risk Factors Associated With Altered Circulating MicroRNA‐125b and Their Influences on Uremic Vascular Calcification Among Patients With End‐Stage Renal Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background MicroRNA‐125b (miR‐125b) has been shown to regulate vascular calcification (VC), and serum miR‐125b levels are a potential biomarker for estimating the risk of uremic VC status.
Chia‐Ter Chao, Tzu‐Hang Yuan, Hsiang‐Yuan Yeh, Hsuan‐Yu Chen, Jenq‐Wen Huang, Huei‐Wen Chen   +5 more
doaj   +1 more source

Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer [PDF]

, 2017
Tumor epithelial cells (TEpCs) and spindle-shaped stromal cells, not associated with the vasculature, of patients with early breast cancer express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), receptor activator ...
Borzone, Francisco Raúl, Chasseing, Norma Alejandra, Choi, Hosoon, Davies, Kevin Mauro, de Luján Calcagno, María, Feldman, Leonardo, García Rivello, Hernán, Giorello, María Belén, Howard, Scott C., Labovsky, Vivian, Martinez, Leandro Marcelo, Matas, Ayelen, Wernicke, Alejandra   +12 more
core   +2 more sources

Serum osteoprotegerin and renal osteodystrophy [PDF]

Nephrology Dialysis Transplantation, 2002
Numerous growth factors and cytokines are known to modulate bone turnover. An important, recently discovered complex involved in osteoclastogenesis is the osteoprotegerin/osteoprotegerin-ligand (OPG/OPGL) cytokine complex, which is produced by osteoblasts.
Coen, Giorgio, Ballanti, Paola, Balducci, Alessandro, Calabria, Santo, Fischer, Maria Stephanie, Jankovic, Ljiljana, Manni, Micaela, Morosetti, Massimo, Moscaritolo, Eleonora, Sardella, Daniela, Bonucci, Ermanno   +10 more
openaire   +3 more sources

Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Elevated levels of osteoprotegerin, a secreted tumor necrosis factor–related molecule, might be associated with adverse outcomes in patients with coronary artery disease. We measured plasma osteoprotegerin concentrations on hospital admission,
Thor Ueland, Axel Åkerblom, Tatevik Ghukasyan, Annika E. Michelsen, Pål Aukrust, Richard C. Becker, Maria Bertilsson, Anders Himmelmann, Stefan K. James, Agneta Siegbahn, Robert F. Storey, Frederic Kontny, Lars Wallentin   +12 more
doaj   +1 more source